Enovis (NYSE:ENOV) Issues FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 3.520-3.730 for the period, compared to the consensus EPS estimate of 3.540. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Analyst Ratings Changes

ENOV has been the topic of several recent research reports. BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. UBS Group reiterated a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Wells Fargo & Company reduced their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Enovis has an average rating of “Moderate Buy” and an average target price of $41.86.

Enovis Price Performance

ENOV stock opened at $30.07 on Thursday. The company’s 50-day moving average is $24.47 and its 200-day moving average is $23.93. Enovis has a 1 year low of $19.14 and a 1 year high of $34.28. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The stock has a market capitalization of $1.73 billion, a PE ratio of -1.51 and a beta of 1.34.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis will post 3.12 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders purchased 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by insiders.

Institutional Trading of Enovis

A number of institutional investors have recently modified their holdings of ENOV. Arax Advisory Partners purchased a new stake in shares of Enovis during the fourth quarter worth $29,000. EverSource Wealth Advisors LLC boosted its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Danske Bank A S purchased a new position in Enovis during the 3rd quarter valued at about $64,000. iSAM Funds UK Ltd purchased a new position in Enovis during the 3rd quarter valued at about $80,000. Finally, Brown Brothers Harriman & Co. purchased a new stake in shares of Enovis in the third quarter worth about $90,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.